Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1)

Objectives The organic anion transporter, OAT1 (SLC22A6), plays a role in the renal elimination of many drugs and environmental toxins. The goal of this study was to identify and functionally characterize OAT1 variants as a first step towards understanding whether genetic variation in OAT1 may contribute to interindividual differences in renal elimination of xenobiotics. Methods As part of a larger study, 276 DNA samples from an ethnically diverse population were screened and 12 coding region variants of OAT1 were identified. The non-synonymous variants were then constructed and characterized in Xenopus laevis oocytes. A small family-based clinical study was conducted to determine the renal elimination of a model OAT1 substrate, adefovir (an antiviral agent) in human subjects who possessed a non-functional variant, OAT1-R454Q. Results Six non-synonymous variants were identified; two (OAT1-R50 H and OAT1-R293W) were present at ≥1% in at least one ethnic population. These two variants exhibited normal uptake of p-aminohippurate, ochratoxin A and methotrexate assayed in X. laevis oocytes. One variant, OAT1-R454Q, was non-functional with respect to the above substrates. In the clinical study, there was no significant decrease in the renal secretory clearance of adefovir in family members heterozygous for OAT1-454Q in comparison to those with the reference transporter, OAT1-454R. Conclusions These data indicate that the coding region of OAT1 has low genetic and functional diversity and suggest that coding region variants of OAT1 may not contribute substantially to interindividual differences in renal elimination of xenobiotics.

[1]  E. Holtzman,et al.  Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). , 1999, Biochemical and biophysical research communications.

[2]  Conrad C. Huang,et al.  Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. , 2002, Pharmacogenetics.

[3]  A. Enomoto,et al.  Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. , 2002, The Journal of pharmacology and experimental therapeutics.

[4]  G. Burckhardt,et al.  Cationic amino acids involved in dicarboxylate binding of the flounder renal organic anion transporter. , 2001, Journal of the American Society of Nephrology : JASN.

[5]  K. Giacomini,et al.  Estimating the contribution of genes and environment to variation in renal drug clearance. , 2003, Pharmacogenetics.

[6]  Conrad C. Huang,et al.  Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. , 2003, Pharmacogenetics.

[7]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[8]  Hao Shen,et al.  An Essential Role of Th1 Responses and Interferon-gamma in Infection-Mediated Suppression of Neoplastic Growth , 2003, Cancer biology & therapy.

[9]  Conrad C. Huang,et al.  Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K. Giacomini,et al.  Arginine 454 and lysine 370 are essential for the anion specificity of the organic anion transporter, rOAT3. , 2001, Biochemistry.

[11]  R. Kim,et al.  Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. , 2003, Molecular cancer therapeutics.

[12]  M. Erion,et al.  Isolation of a family of organic anion transporters from human liver and kidney. , 2001, Biochemical and biophysical research communications.

[13]  G. Reid,et al.  Cloning of a Human Renal p–Aminohippurate Transporter, hROAT1 , 2008, Kidney and Blood Pressure Research.

[14]  F. Tajima.  Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. , 1989, Genetics.

[15]  A. Enomoto,et al.  Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. , 2002, Journal of the American Society of Nephrology : JASN.

[16]  M. Fromm,et al.  Genetic polymorphisms of the human MDR1 drug transporter. , 2003, Annual review of pharmacology and toxicology.

[17]  T. Cihlar,et al.  The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. , 1999, Molecular pharmacology.

[18]  V. Schuster,et al.  Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. , 1999, American journal of physiology. Renal physiology.

[19]  Y. Kanai,et al.  Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. , 1999, American journal of physiology. Renal physiology.

[20]  D. Hartl,et al.  Principles of population genetics , 1981 .

[21]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[22]  T. Cihlar,et al.  NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4–7), 641–648 (2001) HUMAN RENAL ORGANIC ANION TRANSPORTER 1 (hOAT1) AND ITS ROLE IN THE NEPHROTOXICITY OF ANTIVIRAL NUCLEOTIDE ANALOGS , 2003 .

[23]  Conrad C. Huang,et al.  Natural variation in human membrane transporter genes reveals evolutionary and functional constraints , 2003, Proceedings of the National Academy of Sciences of the United States of America.